Xi 'an Wanlong Pharmaceutical was awarded with the title of“2022 quality management advanced unit”
Recently, Xi’an Wanlong Pharmaceutical was awarded with the title of “2022 quality management advanced unit”in the pollof quality management advanced unitconducted by market supervisory authority in Yangling Demonstration zone.
Over the years, Xi’an Wanlong Pharmaceutical attaches great importance to drug quality, always keep in mind the drug quality and safety is the first life of the enterprise. In the process of production and quality management, the company strictly in accordance with the requirements of GMP, and constantly improve and perfect production management level, strengthen the quality security system. Companies with advanced concept, high sense of responsibility to safeguard the safety and efficacy of the drugs, vigorously promote the high quality development of enterprise.
As the“2022 quality management advanced unit”, Xi’an Wanlong Pharmaceutical will continue to demonstrate the original aspiration and mission with responsibility. Moreover, take this as the beginning, and constantly improve the management quality, make the quality management system excellent development, provide consumers with safe and effective drugs and professional health services.
In the awarded manufacturing site, lots of products are produced, such as APIs(L-malic acid, Epalrestat, Tirofiban HCl, Dextran 40, Dextran 70 and Ornidazole) and finished products(Tirofiban hydrochloride Nacl injection, L-Alanyl-L-glutamine injection, Epalrestat tablet, Fexofenadine hydrochloride tablets), besides, GMP certificate are available for these products. Welcome to contact Xi’an Wanlong Pharmaceuticalonline if you are interested with these products.